The development of novel diagnostics and treatment for refractory rhabdomyosarcoma
| Project/Area Number |
22390329
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatric surgery
|
|---|
| Research Institution | Kyoto Prefectural University of Medicine |
|---|
Principal Investigator |
HOSOI Hajime 京都府立医科大学, 大学院・医学研究科・小児発達医学, 教授 (20238744)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IEHARA Tomoko 京都府立医科大学, 大学院・医学研究科小児発達医学, 講師 (20285266)
TSUCHIYA Kunihiko 京都府立医科大学, 大学院・医学研究科小児発達医学, 助教 (90381938)
小野 滋 自治医科大学, 医学部, 准教授 (00315962)
菊地 顕 京都府立医科大学, 医学研究科, 助教 (40453104)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
Fiscal Year 2012: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2011: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2010: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
|
|---|
| Keywords | 横紋筋肉腫 / microRNA / 分子標的療法 / 腫瘍マーカー / 血清診断 / miR-206 / 融合遺伝子 / PAX3-FKHR / 融合遺云子 |
|---|
| Research Abstract |
Presently, there is no body fluid biomarker of rhabdomyosarcoma (RMS). The normalized serum miR-206 expression level could be used to differentiate between RMS and non-RMS tumors, with a sensitivity of 1.0 and a specificity of 0.913. Serum miR-206 expression level can be a novel serum biomarker of RMS.We identified a PAX3-NCOA2 fusion gene in a case of embryonal rhabdomyosarcoma. To understand the role of this translocation in RMS tumorigenesis, we established two types of stable mouse myoblast C2C12 cell lines expressing PAX3-NCOA2 and PAX3-FKHR, respectively. Expression array analysis revealed that RPS6KA1 was commonly upregulated in both cell lines. We are going to validate RPS6KA inhibitor as a novel treatment for rhabdomyosarcoma.
|
Report
(4 results)
Research Products
(27 results)
